Procedural History
569 U.S. 576 (2013)
This landmark Supreme Court case addressed the patent eligibility of human genes, particularly in relation to BRCA1 and BRCA2 gene sequences.
Source: 569 U.S. 576 (2013)
Action: The court ruled that Myriad Genetics' patents on BRCA1 and BRCA2 genes were valid.
Outcome: Plaintiffs appealed the decision.
Significance: The ruling affirmed the patentability of isolated DNA sequences, raising questions about genetic patenting.
Action: The appellate court upheld the validity of Myriad's patents on the BRCA genes.
Outcome: The decision reinforced the distinction between natural phenomena and patentable inventions.
Significance: This ruling sparked further public debate over genetic patents and access to genetic testing.
Action: The Supreme Court heard oral arguments in the case.
Outcome: The Court considered the implications of patenting human genes.
Significance: The arguments highlighted the tension between innovation and access to medical care.
Action: The Supreme Court issued its decision.
Outcome: The Court ruled that Myriad's patents on isolated DNA were invalid.
Significance: This landmark decision clarified that naturally occurring DNA sequences cannot be patented, significantly impacting future bio-pharmaceutical research and genetic testing.
When the Supreme Court finally heard the case, the procedural posture was that the Federal Circuit's ruling had affirmed the validity of Myriad's patents, prompting the plaintiffs to seek a writ of certiorari. The case raised fundamental questions about patent law and genetic research.
The Supreme Court applied a de novo standard of review in determining the validity of the patent claims.
The Supreme Court held that Myriad's claims to isolated DNA were not patentable, thus reversing the decisions of the lower courts.